Biomedical subjects

Francisco Contreras

Publications and source records attributed to Francisco Contreras.

3 recordsLinked to original sources

PubMed2006

Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial.

Perflurocarbon emulsions (PFC) have the capacity of transporting oxygen through the bloodstream and may be safe and effective alternatives to allogeneic blood transfusions during surgical procedures. Perftoran was the PFC used in a randomized clinical trial conducted at Hospital de Especialidades Centro Medico La Raza, Mexico City. The clinical trial took a sample group, n = 30, of patients that were scheduled for elective cardiac valvuloplasty surgery in combination with preoperative acute normovolemic hemodilution and an inspiratory oxygen fraction (FI02) of 1.0. The participants were randomly divided into a Control group (n = 15) and a Perftoran (PFC) group (n = 15). The PFC group had significantly higher intraoperative PaO2 levels and needed less allogeneic red blood cell packs than the Control group. There were no complications or deaths in either group. These results suggest that Perftoran is safe, efficacious, and reduces the need for allogeneic blood and blood derivatives in patients undergoing cardiac surgery.

Adult↗

PubMed2002

Efficacy of a novel chitosan formulation on fecal fat excretion: a double-blind, crossover, placebo-controlled study.

The ability of a novel chitosan formulation to influence gastrointestinal fat absorption in vivo was examined in a double-blind, placebo-controlled, crossover study by determining the content of total fat in feces in two groups of subjects. Twenty-nine normal healthy subjects were recruited for the study. Twenty-four participants completed the test period with the chitosan formulation, and 21 completed the placebo phase of study. During the placebo and the test periods, the subjects were administered six capsules three times daily 10 minutes before meals for three days and for the two days of the stool collection. A daily serving of six tablets of the test compound contained 2100 mg chitosan and 300 mg psyllium husk seeds. In respect to the baseline period, the test compound increased fat excretion significantly whether the test period preceded or proceeded the placebo period (p<0.02 and p<0.05 respectively). In contrast, essentially no changes were seen during the placebo loading periods. Compared to the difference between placebo period and its baseline period, a statistically significant increase in fecal fat excretion was observed over baseline following oral supplementation of a novel formulation of chitosan and psyllium husk seeds [+3.63 gm/day +/- 0.83 (SEM) vs. -0.15 gm/day +/- 0.94 (SEM) (p=0.004)]. The average daily increase in fecal fat of 3-4 grams over control could account for a decrease in calorie consumption of 30-40 kcal per day. A total of 19 subjects completed both parts of the study. Examining the data from these 19 subjects by ANOVA, it was found that the period when the test compounds were given was statistically significantly different from the placebo baseline, placebo experimental, and test baseline periods. Using multiple comparisons, it was ascertained that the novel formulation containing chitosan plus psyllium husk seeds increases fecal fat excretion.

Adult↗

PubMedDate not supplied

Eye disease and care in Latin America and the Caribbean.

In the last decade, health indicators in Latin America and the Caribbean reflect advances. The per capita public expenditure on health care has increased in many countries. Despite these improvements, it is estimated that for every million population in Latin America and the Caribbean, 5,000 are blind and 20,000 are visually impaired; at least 66% of the blindness is attributable to treatable conditions such as cataract. The cataract surgery rate in the region remains low as compared to the industrialized countries, although it is higher than many other regions of the world. The availability of eye care services varies from country to country within the region, and the number of ophthalmologists per million population in the richest countries may be nine times more than in the poorest. Access, defined as the distance between the consumer and the services, is problematic in countries with isolated areas in the rainforest or high mountains, poor road systems, or lack of public transportation. Affordability is an important issue that limits utilization of services by the poorest segments of the population in nearly all countries in Latin America and the Caribbean.

Caribbean Region↗